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Database?  
Databases including PubMed, PsychoINFO, Cumulative Index of Nursing and Allied Health Literature, 
and Health and Psychosocial Instruments were searched for self-report symptom measures that had been 
used among women with either primary dysmenorrhea or perimenstrual symptoms. A total of 15 
measures met inclusion criteria and were included in the final analysis. 
What does this review add?  
This article addresses a void in the literature by critically reviewing content and psychometric properties 
of self-report pain and symptom measures for the common, but understudied problem of primary 
dysmenorrhea. The findings may direct further development and validation of a comprehensive symptom 
measure for descriptive and intervention research on primary dysmenorrhea. 
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Introduction  
Primary dysmenorrhea (PD) is a prevalent and debilitating condition among women of 
reproductive age. Over 25% of women and up to 90% of adolescent girls experience PD; 15-20% report 
PD pain as severe or distressing (Andersch & Milsom, 1982; Banikarim et al., 2000; Davis & Westhoff, 
2001; Durain, 2004; Burnett et al., 2005). In the US, PD is the leading cause of lost work hours in 
women, 10-30% of women miss work because of PD, which translates to a loss of 600 million working 
hours or up to 2 billion dollars annually (Dawood, 1988). In other countries, rates of absenteeism from 
work or school range from 10% to 17% (Svanberg & Ulmsten, 1981; Burnett et al., 2005). Women with 
PD also experience lower physical activity (Chantler et al., 2009), diminished work productivity (Ju et 
al., 2014), and reduced quality of life (Unsal et al., 2010; Iacovides et al., 2013; Nur Azurah et al., 2013). 
Some far-reaching consequences of PD are less well-known. Studies show a high co-occurrence 
of PD and other chronic pain conditions, such as irritable bowel syndromes (IBS) (Altman et al., 2006), 
migraine (Mannix, 2008), and fibromyalgia (Yunus et al., 1989; Shaver et al., 2006). PD can exacerbate 
symptoms of other pain conditions with increased sensitivity to pain both in and outside of the uterine 
referral area (Banikarim et al., 2000; Vincent et al., 2011; Tu et al., 2013). For example, women with IBS 
or urinary calculosis experience more gastrointestinal or urinary symptoms if they have co-existing PD 
(Altman et al., 2006). Scholars suggest that moderate-to-severe menstrual pain could be “a harbinger of 
more pain to come later in life" (p1940) (Vincent et al., 2011). Women with PD are twice as likely to 
develop IBS as women without PD (Olafsdottir et al., 2012). Reports show augmented sensitivity to pain 
and significant brain changes in women with PD, posing risk factors for future pain (Tu et al., 2009, 
2010; Vincent et al., 2011). 
Despite its prevalence and serious consequences, PD is understudied in the pain community, with 
only 0.1% of papers on pain dealing with PD (Berkley & McAllister, 2011). The belief that PD is a 
“normal” condition and that menstrual symptoms are “taboo”, could explain this lack of attention 
(Giamberardino, 2008; Berkley & McAllister, 2011). Historically, stereotyping dysmenorrhea as a 
psychogenic problem might contribute to the lack of research (Dawood, 1988). 
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Symptom assessment is a crucial step toward effective symptom management. To support future 
descriptive and PD intervention research, it is important to evaluate PD symptom measurement tools. 
Other reviews have focused on symptom assessment tools for premenstrual syndrome (PMS) (Budeiri et 
al., 1994; Haywood et al., 2002) which is distinct from PD (Booton & Seideman, 1989) (See Table 1 for 
differences between PD and PMS). The purpose of this paper is to describe and critically review the self-
report tools that have been used to measure pain and other symptoms of PD. This review focuses on 
measurement for research rather than for clinical assessment of PD. 
Methods  
There are two types of dysmenorrhea: primary dysmenorrhea (PD), characterized by abdominal 
or pelvic pain occurring just before or during menstruation in the absence of pelvic pathological findings, 
and secondary dysmenorrhea, defined as painful menstruation in the presence of pelvic pathological 
findings (e.g., endometriosis, uterine fibroids) (International Association for the Study of Pain, 1994; 
Durain, 2004). This review focuses only on PD, and excludes tools designed for measuring symptoms of 
a specific condition related to secondary dysmenorrhea (e.g., endometriosis or uterine fibroids).  
For this review, PD was conceptualized as a symptom-complex secondary to increased 
production of prostaglandins (particularly prostaglandin F2α) and other inflammatory mediators. This 
conceptualization is supported by 1) substantial evidence demonstrating a higher level of menstrual 
prostaglandins in women with PD compared to women without PD (Chan et al., 1981; Dawood, 1981), 2) 
the great similarity between the symptoms of PD and the adverse effects observed in prostaglandin 
administration (Dawood, 2006), and 3) the effectiveness of prostaglandin inhibitors in decreasing 
menstrual prostaglandins and consequently relieving PD symptoms (Chan et al., 1981; Dawood, 1984, 
1988; Marjoribanks et al., 2010). From the pathogenesis point of view, prostaglandins cause uterus 
muscle contraction. The contraction, along with the resulting ischemia, hypoxia, and sensitization of 
nerve endings in the nearby tissues, is responsible for menstrual pain (Lundstrom, 1981; Coco, 1999; 
Dawood, 2006). In addition to pelvic pain and its referred back and thigh pain, prostaglandins also may 
contribute to gastrointestinal symptoms, such as nausea, vomiting, bloating, and change in bowel 
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frequency (Dawood, 1981, 1984; Kinch, 1985; Jarrett et al., 1996). Thus, our review includes tools that 
measure pain as well as other prostaglandin-related symptoms. Our review excludes measures designed to 
exclusively measure PMS/PMDD.  
Literature Search Strategy 
A literature search was performed through January, 2013 using PubMed, Cumulative Index of 
Nursing and Allied Health Literature (CINAHL), PsychoINFO, and Health and Psychosocial Instruments 
(HaPI). Search terms included (“menstrual pain” or “menstrual cramp” or “dysmenorrhea” or “menstrual 
symptoms” or “premenstrual symptoms”) and (“questionnaires” or “instrument” or “measure” or 
“measurement” or “patient report outcome” or “assessment”). The search was not limited by year, but 
was limited to articles published in English. Relevant publications also were identified by using the 
“related articles option” on the databases. Any additional measurement tools identified from the reference 
lists of the retrieved publications were subsequently retrieved and reviewed. Papers were selected for 
further reading if the abstract contained any information related to measurement of symptoms of PD. A 
symptom measurement tool was excluded if it did not contain any menstrual pain-related symptom items. 
Once a measurement tool was identified, the name of the instrument was used as a search term to further 
identify studies reporting its use and its psychometric properties.  
Measurement Tool Evaluation Criteria  
Specific information regarding the purpose(s) of the tool, item content and scoring, symptoms 
measured, timeframe of measurement, reliability, validity, sensitivity (i.e., responsiveness) to change, and 
the populations under study were abstracted from the original studies and subsequent studies using that 
measurement tool. Information was summarized by the first author in a table format; the second and third 
authors checked a selection of articles to assess accuracy of reporting.  
An overall summary of the strengths and weaknesses of the measures is provided in Table 2. The 
review criteria consisted of evaluation of the tools’ validity, reliability, sensitivity to change, 
generalizability, multidimensionality, literacy requirement, and potential for recall bias. The quality of 
attributes for each tool was rated as poor (+), fair (++), good (+++). In scoring the attributes we 
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considered both the soundness of methodologies used and the actual resulting psychometric data. For this 
review, content validity was assessed as a) whether the items in the tool are comprehensive of PD 
symptoms based on the mechanism of prostaglandin release (i.e., pelvic, back and thigh pain, nausea, 
vomiting, bloating, change in bowel frequency) and b) whether the items are relevant or specific to PD. 
For construct validity, we sought evidence of known-groups validity, concurrent validity, 
convergent/discriminant validity, and/or stable factor structure established through factor analysis 
(Nunnally, 1994; Polit, 2012). Reliability was coded based on the overall consistency of a measure across 
time (test-retest reliability) and across items (internal consistency) (Nunnally, 1994; Polit, 2012). 
Sensitivity to change was determined by examining whether a measurement tool was able to identify 
changes in symptoms in response to treatment (Jensen, 2003). Multidimensionality was determined based 
on whether a tool measured dimensions of the pain and symptom experience beyond severity (e.g., pain 
quality, temporal aspects of symptoms, symptom distress, etc.). Generalizability was assessed based on 
the number of studies using a specific tool among women with PD and the diversity of the populations 
across studies in terms of age and country/culture/ethnicity.  
Results 
The review identified a total of 15 measurement tools in three categories: a) generic pain 
measures (n=5), b) tools designed specifically to measure PD symptoms (n=5), and c) tools designed to 
measure menstrual, premenstrual, or perimenstrual symptoms (n=5). Under each category, a description 
of each measurement tool and its psychometric properties is provided, followed by a critique of the tool.  
Category I: Generic Pain Measures  
 Single-item Numerical Rating Scales (NRSs), Visual Analogue Scales (VASs), Verbal Rating Scales 
(VRSs), and Facial Pain Scales (FPSs) 
Description.  
The NRS, VAS, VRS, and FPS are single-item tools designed to measure pain intensity/severity 
in different pain populations and have been widely used in studies of PD. For the NRS, a person is asked 
to rate the pain from 0 to 10 (or 20, 100). While 0 represents “no pain”, the number of upper limit 
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represents the other extreme of pain intensity (e.g., “pain as bad as possible”). A VAS consists of a line, 
usually 10 cm long. Two ends of the line are labeled as the extremes of pain (e.g., “no pain” to “pain as 
bad as it could be”) (Jensen & Karoly, 2011). A VRS consists of a list of adjectives describing different 
levels of pain intensity in rank order. The number of descriptors in a VRS ranges from 4 to 15 (Jensen & 
Karoly, 2011). The FPS measures pain by using illustrations of facial expressions of persons experiencing 
different levels of pain intensity (Jensen & Karoly, 2011). As generic pain measures, these tools have 
undergone extensive psychometric testing, and have evidence of validity , reliability, and sensitivity, and 
are generalizable across different populations with pain ( Jensen, 2003; Jensen & Karoly, 2011), including 
women with menstrual pain (Tugay et al., 2007; Ma et al., 2010).  
Critique  
One major limitation of these single-item measures is that they are not designed to capture the full 
range of symptomology of PD. Women with PD may experience pain at more than one site, and they 
usually also experience other non-pain symptoms (Dawood, 1981, 1984; Kinch, 1985; Jarrett et al., 
1996). Another limitation of these single-item measures is the assumption that pain is a unidimensional 
experience. Only pain intensity is measured, while other dimensions of pain, such as affective 
components, quality, and temporal aspects, are not considered (Melzack, 1975). In addition, there is 
potential for recall bias when such scales are used retrospectively (Jensen, 2003). There is some 
suggestion that a VAS may be more difficult to understand than other single-item pain scales (Larroy, 
2002; Jensen, 2003), however, Gagliese and Melzack (1997) reported that young participants (< 45 years 
old) with chronic arthritis pain (the age range where most women with PD fall) had little problem with the 
VAS.  
The McGill Pain Questionnaire (MPQ)(Melzack, 1975) and the Short-Form MPQ (SF-MPQ)(Melzack, 
1987) 
Description 
The MPQ is a widely used generic pain measure. It consists of 78 descriptors to measure four 
major dimensions of pain: sensory, affective, evaluative, and miscellaneous (Melzack, 1975). The 
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descriptors are read to a respondent who selects those words that best describe his/her feelings and 
sensations at that moment (Melzack, 1975). Three major indices are obtained: 1) the pain rating index 
based on the rank values of the words, 2) the number of words chosen, and 3) the present pain intensity, 
which is the number (0-5) and word (“no pain” to “excruciating”) combination chosen as the indicator of 
overall pain intensity (Melzack, 1975). The SF-MPQ consists of 15 descriptors from the sensory and 
affective categories of the standard MPQ (Melzack, 1987). Each descriptor is rated on an intensity scale 
of 0 (“none”) to 3 (“severe”). Three scores are derived from the sum of the values of the words chosen for 
sensory, affective, and total descriptors. Two additional items measure overall pain intensity, present pain 
intensity, a number from 1 (“mild”) to 5 (“excruciating”), and a VAS (Melzack, 1987). The validity, 
reliability, and sensitivity to change of the MPQ and SF-MPQ have been established among different 
populations including women with PD (Reading, 1979; Eccles, 2005; Chen & Chen, 2010; Katz & 
Melzack, 2011; Wu et al., 2012). 
Critique  
Compared to single item pain measures, the MPQ and SF-MPQ offer a more complete approach 
to pain assessment, measuring not only the sensory component of pain, but also its affective and 
evaluative aspects (Melzack, 1975, 1987; Katz & Melzack, 2011). In addition, the MPQ and SF-MPQ 
capture the quality of pain (e.g., dull, cramping, sharp) and its temporal aspects (e.g., the continuity, 
periodicity) (Jensen, 2003). However, some problems of the MPQ and SF-MPQ may limit their use for 
PD. First, as a generic pain scale, the MPQ and SF-MPQ do not capture the full range of symptomology 
in women with PD. Second, some MPQ and SF-MPQ items may not be relevant to women with PD, for 
example, descriptors such as tingling, itchy, smarting, cold, and freezing are used very infrequently by 
women with PD (Reading, 1979). Third, the MPQ demands a sophisticated literacy level and an extensive 
understanding of English (Burckhardt & Jones, 2003). For example, differentiating between words such 
as “smarting” and “stinging” may be difficult. In addition, understanding and responding to the standard 
78-item MPQ demands a sufficient attention span and can be time consuming.  
Category II: Tools Designed Specifically to Measure PD Symptoms 
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The Menstrual Symptom Questionnaire (MSQ)(Chesney & Tasto, 1975a) 
Description 
The MSQ was designed to differentiate two separate types of PD based on descriptions in the 
literature: spasmodic PD (characterized by cramp-like pain beginning the first day of menstruation 
resulting from uterine contraction) and congestive PD (characterized by dull pain accompanied by 
lethargy and depression prior to the onset of menstruation) (Dalton, 1969; Chesney & Tasto, 1975a). The 
MSQ includes 25 items: 24 items are statements about symptoms (12 characteristics of spasmodic PD, 12 
characteristics of congestive PD). The final item asks respondents to select which type of PD is the most 
accurate description of their experience. For each of the 12 spasmodic items, a score of 5 (“always”) to 1 
(“never”) is selected based on how often the woman experienced the symptom. Conversely, for the 12 
congestive items, scores of 5 to 1 are assigned in reverse order, such that high scores indicate never 
experiencing these symptoms. The final item has two response options: a woman is scored 5 if she 
responds that the description of spasmodic PD is most like her experience and 1 if she chooses the 
congestive PD experience. The total score is calculated by summing responses across the 25 items, with 
higher scores indicating spasmodic PD (Chesney & Tasto, 1975a). The MSQ has good content validity, 
but there is less evidence for construct validity and reliability (Chesney & Tasto, 1975a; Cox, 1977; 
Webster et al., 1979; Nelson et al., 1984; Negriff et al., 2009). The MSQ is sensitive to change (Jay et al., 
1986) and generalizable to women of different ages and with different cultural backgrounds (Chesney & 
Tasto, 1975a, 1975b; Cox, 1977; Nelson et al., 1984; Sigmon & Nelson, 1988).  
Critique  
 The item content of the MSQ is comprehensive of PD, but not all items are relevant. With 
advances in understanding the prostaglandin-mediated pathogenesis of PD, it is now known that both 
spasmodic (e.g., “I have cramps that begin on the first day of my period”) and congestive symptoms (e.g., 
“I am constipated during my period”) co-occur in women with PD (Dawood, 1981; Kinch, 1985; Jarrett et 
al., 1996). Both types of symptoms measured by the MSQ are relevant to PD, however, some of the items 
concerning what women do about their symptoms (e.g., “take a prescription drug” and “use a hot water 
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bottle”) measure behavioral responses to symptoms, not symptoms per se. Construct validity of the MSQ 
is questionable as the dichotomy of congestive and spasmodic symptoms appears not to be sound (Cox, 
1977; Webster et al., 1979), and in subsequent psychometric testing of the MSQ the two-factor structure 
was not supported (Cox, 1977; Nelson et al., 1984; Negriff et al., 2009). Test-retest reliability was 
assessed over a 2-week period, which is problematic in that the reliability of the tool could be confounded 
by the stability/instability of the symptoms over this time span or by existence of recall bias. Another 
problem with the MSQ is that it is unidimensional, measuring only symptom frequency. Lastly, the recall 
period of the MSQ was not described. It is unclear whether women are asked to describe their current or 
recent state (e.g., 28-day recall) or if they are asked to recall symptoms over a longer period of time (e.g., 
one-year recall or recall since menarche). 
The Verbal Multidimensional Scoring System (VMS)(Andersch & Milsom, 1982) 
Description  
The VMS is a grading system developed to assess the prevalence and severity of PD. Information 
on its development was lacking in the report of the original epidemiological study (Andersch & Milsom, 
1982). The VMS includes four categories of severity from Grade 0 (none) to Grade 3 (severe), with each 
grade based on criteria regarding pain severity, effects of pain on daily activities, systemic symptoms, and 
analgesic requirements. For example, the Grade 1 (mild pain) descriptor reads as: “menstruation is 
painful, but seldom inhibits a woman’s normal activity. No systemic symptoms. Analgesics are rarely 
required.”(p 656) (Andersch & Milsom, 1982). The VMS has content validity and construct validity (as 
evidenced by significant correlations between the VMS scores and VAS pain severity scores) (Andersch 
& Milsom, 1982), but little evidence of reliability. It is sensitive to change and generalizable across 
various ages and cultures (Gharloghi et al., 2012; Lindh et al., 2012). 
Critique  
The VMS intends to measure symptoms beyond pelvic / abdominal pain, and thus items are 
comprehensive and relevant to PD. According to Andersch and Milsom, the VMS is advantageous in that 
it is multidimensional, considering four dimensions of dysmenorrhea: pain severity, effects of pain on 
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daily activities, systemic symptoms, and analgesic requirements (Andersch & Milsom, 1982). However, 
rather than scoring each dimension separately, the developers combined the four dimensions together into 
a single score, which constitutes the major limitation of this tool. Suppose a woman rates her 
menstruation as painful, but she does not require analgesics since she uses non-analgesic medications or 
non-medication treatments. Such a woman would not fit into any of the given grading categories. The 
second problem with the VMS is its lack of clarity regarding what the phrase “systemic symptoms” 
means. Without clarification, such wording could be confusing to some respondents. Third, the 
instrument has not been evaluated in terms of reliability. Fourth, the time frame of the measurement is not 
clear; that is, does the VMS measure premenstrual symptoms, menstrual symptoms, or both? Lastly, the 
recall period of the tool is unclear.  
The Retrospective Symptom Scale (RSS, or the Cox RSS) and the Daily Symptom Scale (DSS)(Cox & 
Meyer, 1978) 
Description 
The RSS was developed to measure intensity and frequency (duration) of commonly reported 
physical and emotional dysmenorrheic symptoms (Cox & Meyer, 1978). Women are asked to rate the 
frequency and severity of 18 symptoms on the basis of the experience of their last menstruation. The 
frequency ratings range from 0 (“did not occur”) to 4 (“lasted several days”), and the severity ratings 
range from 0 (“not noticeable”) to 4 (“very severely bothersome”). Total scores are calculated by 
summing the products of frequency and severity ratings for the 18 symptoms (Cox & Meyer, 1978). The 
DSS is identical to the RSS except that it is a daily symptom measurement tool (Cox & Meyer, 1978). 
The construct validity of the DSS and RSS have been supported using the known groups technique (Cox 
& Meyer, 1978). Test-retest reliability of the RSS was assessed by correlating symptom scores in two 
menstrual cycles(Cox & Meyer, 1978). The RSS has been used among young women across cultures and 
is sensitive to change with PD treatment (Sigmon & Nelson, 1988; Harel et al., 1996; Ma et al., 2010; Liu 
et al., 2011). 
Critique  
10 
 
The RSS and DSS have some important merits. First, they offer relatively comprehensive lists of 
symptoms associated with PD based on its pathogenesis, including pain at different locations (i.e., 
cramps, abdominal pain, backache, leg aches, and general aching) and gastrointestinal symptoms (i.e., 
nausea, vomiting, loss of appetite, diarrhea). Second, the instruments take into account the temporal 
aspects of symptoms (i.e., frequency or duration). However, there are several problems with these tools. 
First, the descriptors for the frequency and severity ratings do not exactly correspond to what they intend 
to measure. For example, “lasted less than 3 hours” reads more like a description of symptom duration 
than a description of symptom frequency, and “moderate bothersome” reads more like a description of 
symptom bother or symptom distress than symptom severity per se. Second, some methodological flaws 
in psychometric testing were noticed. Concurrent validity of the RSS was tested using a newly developed 
instrument (i.e., the DSS), the validity of which is unknown. The method used to assess test-retest 
reliability of the RSS was also problematic in that the investigators correlated symptom scores in two 
menstrual cycles (Cox & Meyer, 1978), but symptoms of PD may vary from cycle to cycle (Jarrett et al., 
1996). In addition, the internal consistency of either tool has not been reported. Third, evidence for 
generalizability of the RSS and DSS is still limited, because the RSS has been used only in young women 
with PD (Harel et al., 1996; Ma et al., 2010; Liu et al., 2011), and the DSS is rarely cited in the literature. 
Lastly, recall bias could be an issue for the RSS. 
The Symptom Severity Scale (SSS)(Chesney & Tasto, 1975b)  
Description  
The SSS was developed to measure symptoms associated with dysmenorrhea. Adapted from a 
symptom rating scale developed by Mullen (Mullen, 1971), the SSS measures 15 symptoms, most of 
which are pain and gastrointestinal symptoms (Chesney & Tasto, 1975b). Women are asked to recall the 
degree to which they experienced discomfort during the last menstruation. Each symptom is rated on a 
five-point scale, ranging from 1 (symptom not present) to 5 (very severely). Ratings on each item are 
summed to yield an overall SSS score, with higher values indicating greater symptom severity (Chesney 
& Tasto, 1975b). The SSS has been used among women of a wide age range with PD (Chesney & Tasto, 
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1975b; Sigmon & Nelson, 1988). However, reliability and construct validity of the scale have not been 
reported. It has been reported that the SSS detected therapeutic effects brought about by interventions for 
PD (Chesney & Tasto, 1975b).  
Critique  
The SSS offers a relatively comprehensive list of symptoms associated with dysmenorrhea, 
including pain at different locations (i.e., cramps, abdominal pain, backache, leg aches, and general 
aching) and gastrointestinal symptoms (i.e., nausea, vomiting, loss of appetite, diarrhea). However, 
several problems are noted. First, reliability and construct validity of the scale have not been documented 
in the literature. Second, only one dimension of symptoms, symptom severity, is measured. Third, recall 
bias is a concern for this retrospective measurement tool. Fourth, the generalizability of the tool is limited 
due to the small number of publications and little diversity in culture and ethnicity among populations 
that have been studied.  
Category III: Tools Designed to Measure Perimenstrual Symptoms 
The Menstrual Distress Questionnaire (MDQ)(Moos, 1968) 
Description 
The MDQ is a multi-symptom tool designed to measure menstrual cycle symptomatology. The 
items were derived from 1) a review of research, 2) open-ended questionnaires and/or interviews with 
wives of university graduate students, and 3) symptoms from the Blatt Menopausal Index (Moos, 1968). 
The MDQ contains 47 symptoms grouped into eight subscales: pain, concentration, behavioral change, 
autonomic reactions, water retention, negative affect, arousal, and control (Moos, 1968). The pain 
subscale includes six symptoms: muscle stiffness, headache, cramps, backache, fatigue, and general aches 
and pains. The MDQ measures severity of each symptom: 1) one week before menstruation (i.e., 
premenstrual or PM), 2) during menstrual flow (i.e., menstrual or M), and 3) during the remainder of the 
cycle (i.e., inter-menstrual or IM). A respondent is asked to retrospectively recall her most recent 
menstrual cycle and her worst menstrual cycle. A six-point rating scale is used in which responses range 
from 1 for “no experience” to 6 for “acute or partially disabling experience”. Each woman receives a 
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score on each of the eight subscales in each menstrual phase (PM, M, or IM) by adding together her 
scores for each of the symptoms on that subscale (Moos, 1968). The MDQ has undergone psychometric 
evaluation and has been shown to be sensitive to change, and generalizable across various ages and 
cultures/ethnicities (Moos, 1968; Markum, 1976; Van der Ploeg, 1990; Chen & Chen, 2010). 
Critique  
The MDQ is one of the most widely used measurement tools in menstrual symptom research 
(Hawes & Oei, 1992), and is comprehensive of PD symptoms, however, several problems for use in PD 
should be noted. First, some items on the MDQ may not be relevant to PD (e.g. depression, chest pain, 
and blind spots) based on the prostaglandin-mediated conceptualization. In fact, some symptom items 
listed on the MDQ are not symptoms per se, but rather coping behaviors in response to symptoms (e.g., 
take naps and avoid social activities). Second, the methodologies used to assess psychometric properties 
are flawed (Hawes & Oei, 1992). To assess test-retest reliability, fifteen women were asked to record 
their symptoms daily on nine selected days for each menstrual cycle. Correlating daily symptom scores in 
two consecutive menstrual cycles is problematic due to symptom change across cycles. In addition, the 
small sample may be subject to selection bias (Hawes & Oei, 1992), and the Pearson correlation 
coefficient tends to be inflated for small sample sizes (less than 15) (Reinard, 2006). The construct 
validity of the eight-subscale structure is questionable. The subscales, rather than being grounded in 
theoretical justification, are based on post-hoc exploratory factor analysis (Markum, 1976). Results from 
studies which attempted to replicate the original factor structure obtained by Moos have been inconsistent 
(Van der Ploeg, 1990; Hawes & Oei, 1992). Third, the MDQ is unidimensional and symptom intensity is 
the only dimension being captured. Fourth, recall bias can be an issue if the MDQ is used as a 
retrospective measure. Fifth, the use of the MDQ could be limited by its length and poor readability. Each 
participant needs to rate symptom severity 141 times (47 items * 3 times), and some terms may be 
difficult to understand for non-health professionals (e.g., lowered motor coordination). 
The Daily Symptom Rating Scale (DSRS) (Taylor, 1979)  
Description 
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The DSRS was developed to measure perimenstrual symptoms, with items derived from a list of 
perimenstrual symptoms commonly identified in the literature. Symptoms related to “positive affect” (i.e., 
cheerfulness, outgoingness, and energy) were included because these symptoms were “of theoretical 
interest” to the developers (p. 88) (Taylor, 1979). The DSRS encompasses 17 symptoms grouped into two 
subscales: an affective subscale (10 items) and a somatic subscale (7 items). A six-point scale is used to 
measure the intensity of the symptom experience, in which responses range from 0 for “not at all” to 5 for 
“very large amount”. Women are asked to record their symptoms daily for 5 weeks. A menstrual cycle is 
divided into three phases: premenstrual (PM, 7 days before menstruation), menstrual (M, day one until 
menstruation ceased), and intermenstrual (IM, the remainder of the cycle) phases. Scores on each 
symptom are summarized by averaging the daily scores within each phase (i.e., PM, M, or IM). The 
pelvic or abdominal pain rating in the menstrual phase is taken as the rating for dysmenorrhea. The DSRS 
has fair validity in terms of measuring perimenstrual symptoms and some evidence of reliability (Taylor, 
1979). 
Critique 
As a daily symptom measure, the DSRS reduces recall bias and permits assessment over several 
days to capture daily variation of symptoms. In addition, the brief nature of the DSRS makes it a feasible 
tool for measuring symptoms on a daily basis. However, several problems of the DSRS can be 
recognized. First, The DSRS is not comprehensive of PD symptoms, as it takes only the pelvic or 
abdominal pain rating in the menstrual phase as the rating for dysmenorrhea. Second, some symptom 
items on the DSRS may not be relevant to PD. The ratings for several symptoms (e.g., hopelessness, 
cheerfulness, outgoingness, energy) did not change very much over the entire cycle, and the symptom 
scores for PM and M phases were strongly correlated with that of the IM phase (correlations between .82 
to .93) (Taylor, 1979). One may question whether these symptoms are dispositional attributes (personality 
traits), rather than menstrual symptoms. Menstrual symptoms tend to change over a menstrual cycle, 
while dispositional attributes are relatively stable (McCrae et al., 2002). Third, there has been no evidence 
to support the two-factor structure of the scale, thus construct validity of the somatic and emotional 
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subscales is open to question. Fourth, the methodology used to assess test-retest reliability over 2 cycles is 
flawed (as noted in the critique of the RSS). Fifth, the DSRS is unidimensional; symptom severity is the 
only dimension that is captured. Sixth, the DSRS is infrequently cited in the literature. There is no 
evidence for sensitivity to change, and the generalizability to other populations may be limited. 
The Daily Rating Form (DRF)(Endicott et al., 1986) 
 Description 
The DRF was developed to describe symptom change across the menstrual cycle and to 
summarize patterns of change between the pre- and post- menses periods. Symptom items were selected, 
according to the authors, based on evidence that they describe symptoms that are often more severe 
premenstrually than postmenstrually. In addition, the authors incorporated two social impairment items 
(i.e., impaired work and social withdrawal) and several items of authors’ interest (e.g., alcohol and drug 
use) (Endicott et al., 1986). The DRF includes 20 symptoms grouped into five subscales: “dysphoric 
mood”, “physical discomfort”, “low energy”, “consumption”, and “more alcohol, sex, active.” The DRF 
measures severity of symptoms using a six-point scale of 1 for “none of the feature” to 6 for “extremely 
severe levels of the feature”. A respondent is asked to recall her daily symptoms each evening for an 
entire menstrual cycle. Difference scores in each symptom between postmenstrual days and premenstrual 
days are calculated by subtracting the means of the 5 postmenstrual days from the means of the 3 highest 
premenstrual days. To get the summary score for each subscale, the symptom difference scores under 
each subscale are averaged. PD related symptoms include abdominal pain, back, joint or muscle pain, and 
bloating, all of which are under the subscale of physical discomfort. Construct validity of the DRF was 
established through factor analysis (Endicott et al., 1986), while other psychometric properties have not 
been reported.  
Critique  
As a concurrent symptom measurement tool, the DRF is not subject to recall bias, however, there 
are several problems in using the tool to measure symptoms of PD. First, the DRF does not include a 
comprehensive list of symptoms related to PD. Gastrointestinal symptoms are underrepresented. Second, 
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the developers incorporated items (e.g., drink alcohol, use drugs) that are not relevant to measuring PD 
symptoms and that may not be valid in describing menstrual symptom change. Third, reliability of the 
DRF has not been addressed adequately. Fourth, the construct validity of the DRF was established 
through factor analysis (Endicott et al., 1986), but the theoretical justification of the five-subscale 
structure is unclear. Fifth, the item “back, joint, or muscle pain” covers three types of pain, and it cannot 
differentiate women with only back pain from women with back pain plus joint pain. Sixth, the DRF is 
not a multidimensional scale; symptom severity is the sole dimension that is captured. Seventh, the 
scoring system of the DRF is complicated, which may limit its utility. Lastly, though the DRF has been 
used in different populations (Endicott et al., 1986; Choi et al., 2001; Sit et al., 2011), its generalizability 
to women with PD is not clear due to its limited use in PD-specific populations. 
The Washington Women’s Health Diary (WWHD)(Woods, 1987) and the Menstrual Symptom Severity 
List (MSSL)(Mitchell et al., 1991) 
Description 
The WWHD is a daily symptom rating tool designed to measure perimenstrual symptoms, which 
are defined by the developers as symptoms occurring immediately before and during menstruation. The 
WWHD lists 57 symptoms (40 negative and 17 positive) that were developed based on the Moos MDQ 
(Moos, 1968), the Premenstrual Assessment Form (Halbreich et al., 1982), other literature, and the 
authors’ experience (Woods, 1987). Women are asked to rate their symptom experiences daily for two to 
three menstrual cycles on a 0-4 scale, where 0 represents “not present” and 4 represents “extreme”. A 
total symptom severity score is calculated based on the 40 negative symptoms. Symptom severity scores 
are calculated for days 4 through 10 postmenses, and days -7 through -1 premenses. The means of the 
three most severe symptomatic days are calculated for both phases (Woods, 1987). The 33-item MSSL 
was derived from the WWHD to measure premenstrual symptom severity patterns (including low severity 
or LS pattern, PMS pattern, and premenstrual magnification or PMM pattern). Items on the WWHD were 
removed if (1) they had minimal variance, (2) they were redundant based on the intercorrelations of .80 or 
higher, (3) they were positive symptoms, and (4) they were not in one of the five negative symptom 
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clusters from the principal component analysis (Mitchell et al., 1991). Premenses scores are calculated by 
totaling the scores of days -5 to -1, that is, 5 days before the menses, while postmenses scores are 
calculated by totaling scores of days 6-10 (Mitchell et al., 1991). The WWHD and MSSL have good 
validity and reliability in terms of measuring premenstrual symptoms (Mitchell et al., 1991; Woods et al., 
1995, 1998, 1999), but their sensitivity to change has not been reported. The tools are generalizable to 
women of various ages and culture/ethnicities (Woods, 1987; Woods et al., 1998; Kim, 2004). 
Critique  
Both the WWHD and the MSSL measure a wide range of perimenstrual symptoms, including 
symptoms associated with dysmenorrhea, such as abdominal pain, discomfort (other than cramps), 
backache, uterine or pelvic cramps, general aches and pains, decreased appetite, diarrhea, and nausea. As 
a daily symptom measure, recall bias is reduced as compared with the retrospective symptom measures 
over a longer period of time (e.g., recall symptoms over the most recent menstrual period ) (Woods, 
1987). They are high quality tools for capturing perimenstrual symptoms in general, however, their 
applicability to women with PD may be limited. First, the WWHD and MSSL intend to capture a wide 
spectrum of premenstrual symptoms, including symptoms of PMS and premenstrual magnification (i.e., 
increasing intensity of the symptoms of nonmenstrual conditions) (Woods, 1987; Mitchell et al., 1991). 
Some items on the WWHD may not be relevant to symptom measurement in PD, for example, skin 
disorders, suicidal thoughts, bursts of energy, and intentional self-injury. Second, previous studies 
selected heterogeneous samples that included women with different premenstrual conditions (e.g., 
premenstrual magnification and premenstrual syndrome). Transferability of the psychometric properties 
to the PD-specific population is unclear, because these two tools have not been evaluated specifically 
among women with PD. Moreover, these two measurement tools are unidimensional, covering only the 
dimension of symptom severity.  
Discussion  
Main Issues in PD Symptom Measurement 
Symptoms to measure 
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Lower abdominal/pelvic pain is the most salient symptom among women with dysmenorrhea. 
While it is common to use lower abdominal pain as a key indicator of PD, the release of prostaglandins 
and other inflammatory mediators may produce multiple symptoms (Dawood, 1981, 1984; Kinch, 1985). 
A comprehensive tool should include a broad spectrum of PD symptoms related to the prostaglandin 
mechanism. Because interventions for PD may have differential effects on multiple symptoms, a multi-
symptom measure may be more sensitive to therapeutic change than a tool measuring only pain. 
The three categories of tools reviewed measure different symptoms. Generic pain measures only 
assess pain, and are not comprehensive of symptoms experienced in PD. Tools designed to measure 
perimenstrual symptoms cover a wide range of symptoms, but many are not relevant to dysmenorrhea 
(e.g., symptoms associated with PMDD, premenstrual magnification of psychological problems). In 
addition, because these instruments have been developed for women with various menstrual problems, 
their psychometric properties may not be suitable in PD. Items in tools designed specifically to measure 
PD are both comprehensive of and relevant to PD. Thus, these measures are a logical choice for PD 
research, however, they vary in terms of psychometric properties.  
Psychometric properties of PD-specific tools  
Among the PD-specific tools, the MSQ and the VMS are problematic in terms of validity. The 
validity of the “spasmodic/congestive” construct of the MSQ has been widely criticized by researchers 
(Webster et al., 1979), and the VMS is flawed in using a single score to measure conceptually different 
constructs (i.e., pain severity, pain interference, existence of other symptoms, behavioral response to 
symptoms). The RSS, DSS, and SSS, are most consistent with the conceptualization of PD as a 
prostaglandin-mediated symptom-complex. Evidence of validity and reliability of the RSS was 
established in the original study (Cox & Meyer, 1978), and there is some evidence supporting the 
sensitivity of the RSS to treatment effects (Harel et al., 1996). However, evidence of internal consistency 
reliability of the RSS has not been reported, and psychometric properties of the DSS and SSS have rarely 
been evaluated due to their infrequent use. Some methodological flaws were present in psychometric 
testing, such as testing concurrent validity of the DSS using a newly developed tool and assessing test-
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retest reliability of the RSS across rather than within menstrual cycles. These measures have potential but 
need further development and validation. Given limited generalizability of the tools, an important step 
will be psychometric testing in the country of study’s respective language, particularly where the meaning 
of pain quality descriptors may be lost in translation.  
Relevant dimensions  
Most of the instruments reviewed are unidimensional, evaluating only symptom 
intensity/severity. Measures of other symptom dimensions, such as frequency, duration, quality, and 
distress can provide valuable information in understanding PD and evaluating effects of treatment. The 
RSS and DSS (which measure symptom duration) and the MSD (which measures the time of symptom 
onset) are the only instruments that touch on temporal aspects of symptoms. Temporal aspects of pain and 
other symptoms may be particularly relevant in PD, as symptoms often occur in intermittent episodes 
with symptom-free intervals. Symptom frequency and duration may impact symptom interference with 
daily life, and play a role in selecting symptom interventions (Jensen, 2003). In addition, symptom 
duration is important in identifying symptoms occurring at other phases of the menstrual cycle, and thus 
due to other pelvic pathology (Hofmeyr, 1996).  
Only the MSD and MPQ include items on pain quality (e.g., “not intense, the continuous dull 
aching”, “cramps”) that may be useful in comprehensively understanding a woman’s experience of PD. 
Visceral pain is often described as vague, dull, or periodic, while somatic pain is commonly described as 
sharp and localized (Siddall & Cousins, 1998). Assessing pain quality allows better characterization of 
PD pain components and could facilitate the identification of changes that signal pain sensitization and 
increased risk for future pain conditions. Given the likelihood that some treatments will impact specific 
qualities of pain more than others (Jensen & Karoly, 2011), inclusion of pain quality measures may also 
help test differential effects of PD treatments.  
Symptom distress is rarely evaluated with the tools reviewed. The RSS and the DSS phrase the 
descriptors for intensity in terms of bother (i.e., not noticeable to very severely bothersome), but none of 
the tools were specifically designed to measure PD symptom distress. In addition, it is unknown whether 
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a single global measure of PD symptom distress would be adequate for measuring affective components 
of the symptom experience, or whether a multi-item measure of symptom distress is needed.  
Retrospective recall bias 
The measures reviewed are designed to be used with different recall periods, such as daily (24-
hours) recall (i.e., DSS, DSRS, DRF, WWHD, and MSSL), recall of the most recent menstrual cycle (i.e., 
RSS, SSS, MDQ), and recall of the worst menstrual cycle (i.e., MDQ). Research suggests that recurring 
pain (like menstrual pain) may be remembered less accurately than novel or acute pain (Erskine et al., 
1990). Investigators have suggested that stereotypes about menstruation and PMS can lead women to 
overestimate their menstrual symptoms during recall (Woods et al., 1982; McFarland et al., 1989). 
Underestimation of menstrual symptom intensity has also been reported (Jukic et al., 2008). Though 
menstrual cramps and premenstrual backache were less susceptible to recall bias than were emotional 
symptoms, the concordance between daily recall and recall of the most recent menstrual cycle was low 
(Woods et al., 1982). Generally speaking, longer recall periods are more susceptible to recall bias. An 
ideal measure would use a short recall period. Research comparing 24-hour recall and momentary 
assessment supports the validity of a 24-hour recall for post-operative pain (Jensen et al., 2008) and 
chronic pain in rheumatology patients (Broderick et al., 2008). Given these findings, a 24-hour timeframe 
may be reasonable for measuring PD symptoms, but future research should confirm the validity of this 
recall period.  
Future research 
 Use of PD-specific tools is a logical choice, however, such tools could be strengthened by 
incorporating additional symptom dimensions (e.g., symptom frequency, duration, pain quality, and 
distress) and by conducting psychometric testing using sound methodology and diverse samples. While 
there is no consensus on the optimal set of symptoms for measuring PD, items should be both 
comprehensive of and relevant to current undertanding of PD mechanisms. Currently, prostaglandin-
mediated symptoms should be measured, including pain at different locations (i.e., cramps , backache, 
upper thigh pain, and general aching) and gastrointestinal symptoms (i.e., nausea, vomiting, decreased 
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appetite, diarrhea). Future advances in understanding of PD pathophysiology may result in the need for 
further revision of PD symptom measurement tools. For example, Giamberardino et al. have hypothesized 
that viscero-somatic pain referral is involved in the pathophysiology of PD (Giamberardino, 2003). Their 
work, along with others, may broaden our understanding of PD, necessitating a revision in the symptoms 
that are critical for measurement.  
Given the fact that recall bias is a major concern in retrospective measurement of PD symptoms, 
ecological momentary assessment (EMA) may be a promising method for future research. The symptoms 
of PD are episodic in nature, fluctuating even throughout a single day. In this sense, even a 24-hour recall 
may be subject to bias. Use of EMA would allow research participants to report symptoms at the time of 
occurrence, thereby reducing reliance on memory and improving accuracy. In addition, EMA provides 
multiple assessments over time, rather than a single recall rating. This allows for not only detection of 
symptom pattern over time but also aggregating multiple data points, which increases reliability of the 
measure (Jensen & McFarland, 1993). Moreover, compliance rates for symptom reporting can be 
improved by electronic cueing (Jensen & Karoly, 2011). EMA has not been used among women with PD; 
however, previous research on other pain conditions has shown high compliance and user satisfaction 
(Jensen & Karoly, 2011).  
Limitations 
Limitations of this review should be noted. First, we queried different databases and searched the 
bibliographies of relevant literature, however, our search may have missed qualifying instruments or 
reports of psychometric properties, especially if they were not published in English. Second, our search 
may have missed studies describing the use of a specific tool, especially if a different name for the tool 
was used. Third, we reported only the initial evidence for sensitivity to change (i.e., whether a 
measurement tool was able to show intervention effects in any interventional study), and we did not 
quantify sensitivity to change. Future work shuld evaluate senstitive to change using advanced statistical 
methods (Husted et al., 2000). Despite these limitations, this work adds to the literature by critically 
reviewing self-report pain and symptom measures necessary to advance PD research. Further work on 
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measurement adaptation and validation is needed as outlined above. Following this step, researchers can 
more fully describe the PD symptom experience and develop and test interventions targeted to those 
specific symptom components and their underlying patholophysiology. 
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Table 1. Major Differences Between PD and PMS/PMDD  
 PD  PMS/ PMDD  
Diagnostic Code ICD-9-CM 625.3 
 
ICD-9-CM 625.4 (World Health 
Orgnization (WHO), 2013) 
DSM 311 (for PMDD)(American 
Psychiatric Association et al., 2000) 
Predominant /classic 
symptoms 
Pelvic cramps or pain(World 
Health Orgnization (WHO), 2013) 
Mood symptoms (e.g., depressed 
mood, irritability, affective 
liability,anger)(American Psychiatric 
Association et al., 2000; World Health 
Orgnization (WHO), 2013) 
Secondary/ other 
symptoms 
Referred back, thigh pain, GI 
symptoms (e.g. nausea, vomiting 
and change in bowel frequency) 
secondary to the release of PGs 
and other inflammatory substances 
(Dawood, 1981, 1984)  
Symptoms related to salt and water 
retention (weight gain, swelling and 
bloating) (World Health Orgnization 
(WHO), 2013)  
Timing of Symptoms Start several hours before or 
during menstruation;  
May get worse once menstruation 
begins (Booton & Seideman, 
1989)  
Start several days before menstruation;  
Typically relieved with the onset of 
menstruation (Booton & Seideman, 
1989; Coco, 1999)  
Classic Medical 
Treatment  
NSAIDs, OCs (Coco, 1999) Antidepressants particularly SRIs 
(Douglas, 2002) 
 
PD, primary dysmenorrhea; PMS, premenstrual syndrome; PMDD, premenstrual dysphoric disorder; 
NSAIDs, non-steroidal anti-inflammatory drugs; PGs, prostaglandins, OCs, oral contraceptives. SRIs, 
serotonin reuptake inhibitors; ICD: International Classification of Diseases; DSM, Diagnostic and 
Statistical Manual of Mental Disorders 
 
 Table 2. Summary of strengths of the self-report pain and symptom measures for PD  
Category Generic Pain 
Measures 
Tools Designed Specifically to Measure 
PD Symptoms  
Tools Designed to Measure Perimenstrual 
Symptoms 
 NRSs, 
VASs, 
VRSs, 
FPSs 
MPQ/ 
SF-MPQ 
MSQ  VMS  RSS 
 
DSS  
 
SSS  MDQ  DSRS  DRF  WWHD  MSSL 
Valid (Content) 
• Comprehensiveness 
• Relevance  
 
++ 
 
+++ 
 
++ 
 
++ 
 
+++ 
 
+++ 
 
+++ 
 
+++ 
 
+++ 
 
+++ 
 
+++ 
 
+++ 
 
+++ 
 
+++ 
 
+++  
 
++ 
 
++ 
 
++ 
 
++  
 
++ 
 
+++ 
 
++ 
 
+++ 
 
++ 
Valid (Construct) +++ +++ ++  +++ +++  +++  + ++  +++ ++ +++ +++ 
Reliable (Test-retest)  +++ +++ ++  + ++ + + ++ ++ + +++ +++ 
Reliable (Internal 
consistency)  
n/a +++ + + + + + +++ +++ + +++ +++ 
Sensitive to change +++  +++ +++ +++ +++ +++ +++ +++  + + + + 
Generalizable 
• # of publications  
• Wide age range 
• Diverse 
culture/ethnicity  
 
+++* 
+++ 
+++ 
 
+++ 
+++ 
+++ 
 
+++ 
+++ 
+++ 
 
+++ 
+++ 
+++  
 
++ 
++ 
+++ 
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++ 
+++ 
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+++ 
+++ 
+++ 
 
+ 
++ 
+ 
 
+ 
+++ 
+++ 
 
+ 
+++ 
+++ 
 
+ 
+++ 
+++ 
Multidimensional  + +++ + + +++  +++  + + + + + + 
Does NOT require high 
literacy 
+++ + +++ +++ +++ +++ +++ + +++ +++ +++ +++ 
1 
 
NOT subject to recall 
bias 
depends 
on time 
frame 
specified 
depends 
on time 
frame 
specified 
+ +  + +++ + + +++ +++ +++ +++ 
Does NOT combine 
symptoms and coping 
behaviors 
+++ +++ + + +++ +++ +++ + +++ + +++ +++ 
 
NRSs, Numerical Rating Scales; VASs, Visual Analogue Scales; VRSs, Verbal Rating Scales; FPSs, Facial Pain Scales; MPQ, the McGill Pain 
Questionnaire (Melzack, 1975); SF-MPQ, the Short-form McGill Pain Questionnaire (Melzack, 1987); MSQ, the Menstrual Symptom 
Questionnaire (Chesney & Tasto, 1975a); VMS, the Verbal Multidimensional Scoring System (Andersch & Milsom, 1982); RSS, the 
Retrospective Symptom Scale (Cox & Meyer, 1978); DSS, the Daily Symptom Scale (Cox & Meyer, 1978); SSS, the Symptom Severity Scale 
(Chesney & Tasto, 1975b); MDQ, the Menstrual Distress Questionnaire (Moos, 1968); DSRS, the Daily Symptom Rating Scale (Taylor, 1979); 
DRF, the Daily Rating Form (Endicott et al., 1986); WWHD, the Washington Women’s Health Diary (Woods, 1987); & MSSL, the Menstrual 
Symptom Severity List (Mitchell et al., 1991); n/a, not applicable.  
*+ for FPSs 
For “valid” and “reliable”:  
+, the criterion has NOT been tested OR the criterion is NOT satisfied.  
++, the criterion has been tested. However, the testing method was flawed, OR the test results were either unsatisfactory or inconsistent.  
+++, the criterion has been tested with sound methodology and acceptable results, OR the criterion is satisfied.  
For “sensitive to change”: 
+, there is no intervention study using the instrument OR there is no intervention study showing positive results brought about by the 
intervention using the instrument.  
+++, there is at least one study (the outcome of which was measured by the instrument) showing positive intervention effect. 
2 
 
For “generalizable” (# of studies): 
+, ≤3 studies on PD. 
++, 4-10 studies on PD. 
+++, >10 studies on PD.  
For “generalizable” (age): 
+, previous study samples included only adolescent OR only college age women.  
++, previous study samples included both adolescent AND college age women, BUT no middle age women. 
+++, previous study samples included women of different ages across the reproductive spectrum.  
For “generalizable” (diverse culture/ethnicity): 
+, the tool has been used only in one country/race/ethnicity. 
++, the tool has been in two countries/races/ethnicities.  
+++, the tool has been used in ≥ 3 countries/races/ethnicities.  
 For “multidimensional”: 
+, the tool only measures one dimension (e.g., symptom intensity/severity) of PD symptom experience.  
+++, the tool measures more than one dimension of symptom experience (i.e., measures symptom intensity, duration, and frequency, etc.).  
 
 
 
 
